ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) has been assigned a consensus recommendation of "Hold" from the twenty analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $22.72.

ACAD has been the subject of several recent analyst reports. JPMorgan Chase & Co. lowered shares of ACADIA Pharmaceuticals from an "overweight" rating to a "neutral" rating in a report on Tuesday, June 21st. The Goldman Sachs Group decreased their price objective on shares of ACADIA Pharmaceuticals from $20.00 to $15.00 and set a "neutral" rating for the company in a report on Tuesday, August 9th. HC Wainwright lifted their price target on shares of ACADIA Pharmaceuticals from $20.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, August 9th. SVB Leerink decreased their price target on shares of ACADIA Pharmaceuticals from $27.00 to $21.00 and set an "outperform" rating for the company in a report on Tuesday, August 9th. Finally, Cowen decreased their price target on shares of ACADIA Pharmaceuticals from $32.00 to $21.00 and set an "outperform" rating for the company in a report on Monday, August 8th.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in ACADIA Pharmaceuticals by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 12,580,814 shares of the biopharmaceutical company's stock valued at $304,707,000 after purchasing an additional 265,448 shares during the last quarter. State Street Corp raised its position in shares of ACADIA Pharmaceuticals by 30.4% during the 2nd quarter. State Street Corp now owns 6,593,950 shares of the biopharmaceutical company's stock worth $92,909,000 after buying an additional 1,536,756 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of ACADIA Pharmaceuticals by 4.9% during the 1st quarter. JPMorgan Chase & Co. now owns 2,310,355 shares of the biopharmaceutical company's stock worth $55,957,000 after buying an additional 108,179 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ACADIA Pharmaceuticals by 7.1% during the 4th quarter. Geode Capital Management LLC now owns 2,164,152 shares of the biopharmaceutical company's stock worth $50,511,000 after buying an additional 143,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of ACADIA Pharmaceuticals by 42.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,181,923 shares of the biopharmaceutical company's stock worth $27,586,000 after buying an additional 355,077 shares in the last quarter. 92.48% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The company had revenue of $134.56 million during the quarter, compared to analyst estimates of $130.06 million. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative return on equity of 41.18%. The firm's revenue for the quarter was up 16.8% compared to the same quarter last year. During the same period last year, the business earned ($0.27) EPS. On average, sell-side analysts expect that ACADIA Pharmaceuticals will post -1.3 EPS for the current year.

ACADIA Pharmaceuticals Company Profile

(Get Rating)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Featured Stories

• Get a free copy of the StockNews.com research report on ACADIA Pharmaceuticals (ACAD)
• Magna International is Your Auto and EV One-Stop Shop Stock
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30
• This Is A Memorable Time To Buy Into Micron Technology
• Declining Profits Challenge the CarMax Value Proposition

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.